Monte Rosa Therapeutics, INC Form 4 insider transactions

Markus Warmuth, President & CEO and a Director of Monte Rosa Therapeutics, Inc., sold 9,500 shares of common stock on July 16, 2026 for $23.18 per share.

Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, Inc., sold 4,351 shares of common stock on July 15, 2026 for $23.38 per share.

Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, Inc., executed a series of transactions involving the purchase and sale of company common stock on July 6, 2026, under a pre-established Rule 10b5-1 trading plan.

Ali Behbahani, a Director at Monte Rosa Therapeutics, Inc., reported transactions involving common stock on July 1, 2026, primarily through investment entities.

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, Inc., executed a Rule 10b5-1 trading plan transaction involving the acquisition and disposition of common stock.

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, Inc., executed a Rule 10b5-1 trading plan transaction on June 29, 2026, involving the acquisition of 6,000 shares and the disposition of 6,000 shares.

Anthony Manning, a Director at Monte Rosa Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock.

Filip Janku, Chief Medical Officer at Monte Rosa Therapeutics, executed a series of stock transactions under a Rule 10b5-1 trading plan.

Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, Inc., reported transactions involving common stock and stock options on June 23, 2026, executed under a Rule 10b5-1 trading plan.

Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, Inc., executed a Rule 10b5-1 plan transaction involving the purchase and sale of company common stock.

Director Ali Behbahani was granted 25,800 stock options in Monte Rosa Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Andrew Schiff was granted 25,800 stock options in Monte Rosa Therapeutics, Inc. as part of standard equity compensation.

Director Anthony M. Manning was granted 25,800 stock options in Monte Rosa Therapeutics, Inc. as part of standard equity compensation.

Director Jan Skvarka was granted 25,800 stock options in Monte Rosa Therapeutics, Inc. as part of standard equity compensation.

Director Kimberly Blackwell was granted 25,800 stock options in Monte Rosa Therapeutics, Inc. as part of a standard equity incentive.

Markus Warmuth, President & CEO of Monte Rosa Therapeutics, Inc., reported the sale of common stock totaling 5,466 shares under a pre-arranged Rule 10b5-1 trading plan.

Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, executed trades involving common stock and stock options under a pre-arranged Rule 10b5-1 plan.

Chief Operating Officer Jennifer Champoux exercised 2,175 stock options and subsequently sold the shares under a Rule 10b5-1 plan.

Monte Rosa Therapeutics' Chief Operating Officer, Jennifer Champoux, executed a Rule 10b5-1 plan involving the acquisition and sale of company stock.

Director Anthony M. Manning exercised 10,000 stock options and subsequently sold the shares on May 21, 2026.

Markus Warmuth, President & CEO of Monte Rosa Therapeutics, Inc., reported the sale of 5,467 shares of common stock on May 1, 2026, executed under a Rule 10b5-1 trading plan.

Philip Nickson, Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc., reported a sale of 5,845 shares of common stock.

Matthew Bowen, Principal Accounting Officer at Monte Rosa Therapeutics, Inc., reported transactions involving the acquisition of restricted stock units and stock options.

Monte Rosa Therapeutics' Principal Accounting Officer, Edmund Dunn, sold 139 shares of common stock to cover tax withholding obligations.

Monte Rosa Therapeutics CEO Markus Warmuth sold 5,466 shares of common stock for $17.9243 per share under a pre-arranged trading plan.

Monte Rosa Therapeutics' Principal Accounting Officer, Edmund Dunn, exercised stock options and subsequently sold shares in two separate transactions.

Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, sold 9,189 shares of common stock for $19.4973 per share.

Monte Rosa Therapeutics CEO Markus Warmuth sold 5,466 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 trading plan.

Monte Rosa Therapeutics' Chief Business & Legal Officer, Philip Nickson, reported the acquisition of restricted stock units and stock options, alongside a sale of shares for tax obligations.

Monte Rosa Therapeutics' Chief Operating Officer, Jennifer Champoux, reported the grant of 35,000 restricted stock units and 158,000 stock options, alongside a tax-related sale of 2,629 common shares.